Table 1 Comparison of gene centering with a subgroup-specific strategy on the UNC prototypic tumor set a
From: Molecular subtyping for clinically defined breast cancer subgroups
Prediction (%) | |||||||
|---|---|---|---|---|---|---|---|
Dataset | Subgroup | Gene-centering method | Basal-like | HER2-enriched | LumA | LumB | Normal-like |
Prototypic basal | Basal-like | Standard | 12 (21.1) | 8 (14) | 17 (29.8) | 16 (28.1) | 4 (7) |
(n = 57) | Subgroup-specific | 56 (98.2) | 0 (0) | 0 (0) | 0 (0) | 1 (1.8) | |
Prototypic HER2 | Her2-enriched | Standard | 8 (22.9) | 7 (20) | 10 (28.6) | 6 (17.1) | 4 (11.4) |
(n = 35) | Subgroup-specific | 2 (5.7) | 27 (77.1) | 1 (2.9) | 5 (14.3) | 0 (0) | |
Prototypic LumA | Luminal A | Standard | 7 (30.4) | 1 (4.3) | 6 (26.1) | 3 (13) | 6 (26.1) |
(n = 23) | Subgroup-specific | 0 (0) | 0 (0) | 21 (91.3) | 1 (4.3) | 1 (4.3) | |
Prototypic LumB | Luminal B | Standard | 2 (16.7) | 3 (25) | 3 (25) | 2 (16.7) | 2 (16.7) |
(n = 12) | Subgroup-specific | 0 (0) | 0 (0) | 0 (0) | 12 (100) | 0 (0) | |
Prototypic normal | Normal-like | Standard | 2 (16.7) | 2 (16.7) | 2 (16.7) | 2 (16.7) | 4 (33.3) |
(n = 12) | Subgroup-specific | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 12 (100) | |